Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D.

Sci Rep. 2016 Nov 23;6:36462. doi: 10.1038/srep36462.

2.

A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.

Gong L, Proulle V, Fang C, Hong Z, Lin Z, Liu M, Xue G, Yuan C, Lin L, Furie B, Flaumenhaft R, Andreasen P, Furie B, Huang M.

J Cell Mol Med. 2016 Oct;20(10):1851-60. doi: 10.1111/jcmm.12875.

3.

Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Li SH, Reinke AA, Sanders KL, Emal CD, Whisstock JC, Stuckey JA, Lawrence DA.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4941-9. doi: 10.1073/pnas.1216499110.

4.

Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Fjellström O, Deinum J, Sjögren T, Johansson C, Geschwindner S, Nerme V, Legnehed A, McPheat J, Olsson K, Bodin C, Paunovic A, Gustafsson D.

J Biol Chem. 2013 Jan 11;288(2):873-85. doi: 10.1074/jbc.M112.371732.

5.

uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin.

Wang L, Ly CM, Ko CY, Meyers EE, Lawrence DA, Bernstein AM.

Invest Ophthalmol Vis Sci. 2012 Jul 13;53(8):4765-75. doi: 10.1167/iovs.12-10042.

6.
7.

A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T.

J Cereb Blood Flow Metab. 2010 May;30(5):904-12. doi: 10.1038/jcbfm.2009.272.

8.

Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.

Cale JM, Li SH, Warnock M, Su EJ, North PR, Sanders KL, Puscau MM, Emal CD, Lawrence DA.

J Biol Chem. 2010 Mar 12;285(11):7892-902. doi: 10.1074/jbc.M109.067967.

9.

Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).

El-Ayache NC, Li SH, Warnock M, Lawrence DA, Emal CD.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):966-70. doi: 10.1016/j.bmcl.2009.12.051.

10.

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105.

Supplemental Content

Support Center